Business Wire

Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials

CHICAGO--(BUSINESS WIRE)--Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to ...

ElevateBio Achieves Sixth Consecutive Year of Revenue Growth Driven by Expansion of its Genetic Medicine Technology and Manufacturing Business

Achieved 98% manufacturing batch success rate at BaseCamp across cell therapy, viral vector, and mRNA– Positioned U.S.-based biomanufacturing ...
Labmate Online

New AAV supplement enhances gene therapy production

Ajinomoto CELLiST Korea, part of the Ajinomoto Group, has launched CELLiST™ AAV Production Supplement 1, a new culture medium ...
TMCnet

Bionova Scientific and Syenex Forge Strategic Alliance to Expand Access to High-Quality Plasmid DNA for Advanced Therapies

Bionova Scientific LLC, an Asahi Kasei company and a bespoke contract development and manufacturing organization (CDMO), announced a strategic manufacturing alliance with Syenex, a genetic medicines ...
WIVB-TV

CellFE® Partners with DKFZ and TcellTech to Advance DNA Vector Genetic Engineering for Cellular Therapies

ALAMEDA, Calif., April 30, 2025 /PRNewswire/ -- CellFE, a leader in non-viral gene editing technology, today announced a strategic collaboration with the Harbottle Lab at German Cancer Research Center ...
Morningstar

Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials

Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in ...